Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00206622 · ClinicalTrials.gov registry record · Phase 4
Efficacy and Safety Study in Postmenopausal Women to Determine the Lowest Effective Dose for Relief of Moderate to Severe Hot-Flushes
A Phase 4 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 4
- Development phase
- 425
- Enrollment target
NCT00206622: Completed Phase 4 study, sponsored by Bayer.
NCT00206622 is a Phase 4 study that has completed, run by Bayer. The registered enrollment target is 425 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (18% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00206622, a Phase 4 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 425 participants
- Enrollment target
Study Summary
To determine the lowest effective dose of estradiol by comparing E2/LNG (2.2mg/0.69mg) and E2 (1.0mg) dose with placebo in decreasing the frequency and severity of moderate to severe hot flushes in postmenopausal women
Interventions
- DRUG Climara PRO (Estradiol / Levonorgestrel transdermal)
- DRUG Menostar (Estradiol transdermal)
- DRUG Placebo transdermal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 425 participants |
| Start Date | 2004-12 |
| Est. Completion | 2006-02 |
| Phase | Phase 4 |
What the finished NCT00206622 record still lists
NCT00206622 is an interventional study that assigns participants to a tested intervention. The registered 425 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (18% lower).
The record links to 0 conditions, and to 3 interventions - of which Climara PRO (Estradiol / Levonorgestrel transdermal) is the first listed.
NCT00206622 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00206622 about?
NCT00206622 is a clinical study titled "Efficacy and Safety Study in Postmenopausal Women to Determine the Lowest Effective Dose for Relief of Moderate to Severe Hot-Flushes". To determine the lowest effective dose of estradiol by comparing E2/LNG (2.2mg/0.69mg) and E2 (1.0mg) dose with placebo in decreasing the frequency and severity of moderate to severe hot flushes in postmenopausal women
What is the current status of trial NCT00206622?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 425 participants. The study started on 2004-12. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00206622?
The interventions under investigation include: Climara PRO (Estradiol / Levonorgestrel transdermal) (DRUG), Menostar (Estradiol transdermal) (DRUG), Placebo transdermal (DRUG).
Who is sponsoring clinical trial NCT00206622?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00206622's enrollment target sits among peer trials
425 197th of 2000 higher than 1,802 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04265430 · 425 participants · Phase 4
Serial Magnetic Resonance Imaging for the Prediction of Radiation-Induced Changes in Normal Tissue of Patients With Oral Cavity or Skull Base Tumors
- NCT04278690 · 425 participants · NA
Supporting Safe Use of Medications by Parents After Infant Discharge From the Neonatal Intensive Care Unit
- NCT05321368 · 425 participants · NA
A Cardiometabolic Health Program Linked With Clinical-Community Support and Mobile Health Telemonitoring to Reduce Health Disparities
- NCT05340738 · 425 participants · NA
AI-Based Fidelity Feedback to Enhance CBT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia